Bioblast Pharma

Hope should not be rare

Latest Developments Archive

Latest Developments Archive

  • September 10, 2015
  • Bioblast Pharma
  • Latest developments

Bioblast Pharma Augments Leadership Team and Establishes U.S. Headquarters in New Haven, Connecticut

Appoints Former NPS and ViroPharma Executive, Paul Firuta as Chief Commercial Officer

New Haven, CT – September 10, 2015 – Bioblast Pharma Ltd., (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today that it has appointed Paul Firuta to the newly-created position of Chief Commercial Officer. Mr. Firuta will be a member of Bioblast’s Executive Committee and will oversee, in particular, the commercial strategy for Cabaletta (IV trehalose) – the Company’s lead product candidate set to commence Phase 3 clinical development this year in the United States and Canada.

Continue reading

  • September 8, 2015
  • Bioblast Pharma
  • Latest developments

Bioblast Pharma to Present at Rodman & Renshaw Conference on September 10

TEL AVIV, Israel, September 8, 2015 — Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster, President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 17th Annual Global Investment Conference 2015.

Rodman & Renshaw 17th Annual Global Investment Conference 2015
Date: September 10, 2015
Time: 4:15pm Eastern Time
Webcast: https://wsw.com/webcast/rrshq25/orpn

Continue reading

  • February 2, 2015
  • Bioblast Pharma
  • Latest developments

Bioblast Announces Key Leadership Changes

Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced key senior leadership changes designed to support the Company’s global clinical efforts, operational scale-up, and pre-commercialization activities.

Colin Foster, a 25-year veteran of the life sciences industry has joined Bioblast as its President and Chief Executive Officer and a member of its Board of Directors, effective immediately. Dalia Megiddo, MD, co-founder and former Chief Executive Officer, has been named to the newly-created position of Chief Development Officer and will remain a member of the Board of Directors.

Continue reading

Pages